scholarly journals iRGD Peptide-Mediated Liposomal Nanoparticles with Photoacoustic/Ultrasound Dual-Modality Imaging for Precision Theranostics Against Hepatocellular Carcinoma

2021 ◽  
Vol Volume 16 ◽  
pp. 6455-6475
Author(s):  
Huipu Li ◽  
Shasha Shi ◽  
Meng Wu ◽  
Wei Shen ◽  
Jianli Ren ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Dual Modality ◽  
Dual Modality Imaging ◽  
Liposomal Nanoparticles

Abstract 5297: Dual-modality imaging of hepatocellular carcinoma

2011 ◽  
Author(s):  
David Corn ◽  
Jack Jesberger ◽  
Jeffrey Kolthammer ◽  
Christopher Flask ◽  
Zhenghong Lee
Keyword(s):  
Hepatocellular Carcinoma ◽  
Dual Modality ◽  
Dual Modality Imaging

Theranostic micelles based on upconversion nanoparticles for dual-modality imaging and photodynamic therapy in hepatocellular carcinoma

Nanoscale ◽  
2018 ◽  
Vol 10 (14) ◽  
pp. 6511-6523 ◽  
Author(s):  
Yong Han ◽  
Yanli An ◽  
Gang Jia ◽  
Xihui Wang ◽  
Chen He ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Photodynamic Therapy ◽  
Therapeutic Strategies ◽  
Upconversion Nanoparticles ◽  
Curative Surgery ◽  
Dual Modality ◽  
Dual Modality Imaging

Hepatocellular carcinoma (HCC) is frequently metastatic once diagnosed and less likely to respond to curative surgery, emphasizing the need for the development of more sensitive and effective diagnostic and therapeutic strategies.

Biocompatible melanin based theranostic agent for in vivo detection and ablation of orthotopic micro-hepatocellular carcinoma

2020 ◽  
Vol 8 (15) ◽  
pp. 4322-4333
Author(s):  
Kang Chen ◽  
Qiaolin Li ◽  
Xingyang Zhao ◽  
Jinde Zhang ◽  
Haosong Ma ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Dual Modality ◽  
Theranostic Agent ◽  
Photothermal Ablation ◽  
In Vivo Detection ◽  
Therapeutic Outcomes ◽  
Dual Modality Imaging

Enhanced photoacoustic performance and therapeutic outcomes of melanin-based organic agents for dual-modality imaging and photothermal ablation of orthotopic hepatocellular carcinoma.

scholarly journals Tumor-targeted Dual-modality Imaging to Improve Intraoperative Visualization of Clear Cell Renal Cell Carcinoma: A First in Man Study

Theranostics ◽  
2018 ◽  
Vol 8 (8) ◽  
pp. 2161-2170 ◽  
Author(s):  
Marlène C. Hekman ◽  
Mark Rijpkema ◽  
Constantijn H. Muselaers ◽  
Egbert Oosterwijk ◽  
Christina A. Hulsbergen-Van de Kaa ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Clear Cell ◽  
Cell Renal Cell Carcinoma ◽  
Dual Modality ◽  
Dual Modality Imaging ◽  
Intraoperative Visualization

scholarly journals Initial in vitro and in vivo assessment of Au@DTDTPA-RGD nanoparticles for Gd-MRI and 68Ga-PET dual modality imaging

2015 ◽  
Vol 2 (Suppl 1) ◽  
pp. A89 ◽  
Author(s):  
Charalmpos Tsoukalas ◽  
Gautier Laurent ◽  
Gloria Jiménez Sánchez ◽  
Theodoros Tsotakos ◽  
Rana Bazzi ◽  
...  
Keyword(s):  
Dual Modality ◽  
Dual Modality Imaging ◽  
In Vivo Assessment

scholarly journals Dual-Modality Imaging of Cancer with SPECT/CT

2002 ◽  
Vol 1 (6) ◽  
pp. 449-458 ◽  
Author(s):  
Bruce H. Hasegawa ◽  
Kenneth H. Wong ◽  
Koji Iwata ◽  
William C. Barber ◽  
Andrew B. Hwang ◽  
...  
Keyword(s):  
Computed Tomography ◽  
Em Algorithm ◽  
Photon Emission ◽  
Imaging Systems ◽  
Patient Specific ◽  
Emission Computed Tomography ◽  
Functional Information ◽  
Dual Modality ◽  
Photon Attenuation ◽  
Dual Modality Imaging

Dual-modality imaging is an in vivo diagnostic technique that obtains structural and functional information directly from patient studies in a way that cannot be achieved with separate imaging systems alone. Dual-modality imaging systems are configured by combining computed tomography (CT) with radionuclide imaging (using positron emission tomography (PET) or single-photon emission computed tomography (SPECT)) on a single gantry which allows both functional and structural imaging to be performed during a single imaging session without having the patient leave the imaging system. A SPECT/CT system developed at UCSF is being used in a study to determine if dual-modality imaging offers advantages for assessment of patients with prostate cancer using111 In-ProstaScint®, a radiolabeled antibody for the prostate-specific membrane antigen.111 In-ProstaScint® images are reconstructed using an iterative maximum-likelihood expectation-maximization (ML-EM) algorithm with correction for photon attenuation using a patient-specific map of attenuation coefficients derived from CT. The ML-EM algorithm accounts for the dual-photon nature of the111 In-labeled radionuclide, and incorporates correction for the geometric response of the radionuclide collimator. The radionuclide image then can be coregistered and overlaid in color on a grayscale CT image for improved localization of the functional information from SPECT. Radionuclide images obtained with SPECT/CT and reconstructed using ML-EM with correction for photon attenuation and collimator response improve image quality in comparison to conventional radionuclide images obtained with filtered backprojection reconstruction. These results illustrate the potential advantages of dual-modality imaging for improving the quality and the localization of radionuclide uptake for staging disease, planning treatment, and monitoring therapeutic response in patients with cancer.

In vivo NIRF and MR dual-modality imaging using glycol chitosan nanoparticles

2012 ◽  
Vol 163 (2) ◽  
pp. 249-255 ◽  
Author(s):  
Jaehong Key ◽  
Christy Cooper ◽  
Ah Young Kim ◽  
Deepika Dhawan ◽  
Deborah W. Knapp ◽  
...  
Keyword(s):  
Chitosan Nanoparticles ◽  
Glycol Chitosan ◽  
Dual Modality ◽  
Dual Modality Imaging
Sign in / Sign up

Export Citation Format

Share Document